Leronlimab increases PD-L1 expression on circulati
Post# of 155056
(Total Views: 390)
Posted On: 07/02/2025 7:38:36 PM
Leronlimab increases PD-L1 expression on circulating tumor cells, potentially converting "cold" tumors to "hot" ones, enhancing immune response in metastatic triple-negative breast cancer.
In a study, 88% of patients receiving leronlimab showed increased PD-L1 levels, suggesting improved responsiveness to immune checkpoint inhibitors.
Leronlimab's mechanism may offer new treatment options for solid tumors with low PD-L1 levels, traditionally resistant to immunotherapy.
Further studies are needed to confirm leronlimab's potential in transforming tumor environments and improving outcomes in solid tumor oncology
Read in full
https://www.curetoday.com/view/leronlimab-lin...ast-cancer
In a study, 88% of patients receiving leronlimab showed increased PD-L1 levels, suggesting improved responsiveness to immune checkpoint inhibitors.
Leronlimab's mechanism may offer new treatment options for solid tumors with low PD-L1 levels, traditionally resistant to immunotherapy.
Further studies are needed to confirm leronlimab's potential in transforming tumor environments and improving outcomes in solid tumor oncology
Read in full
https://www.curetoday.com/view/leronlimab-lin...ast-cancer
(2)
(1)